Mutational Load Assessment for Barrett's Esophageal Cancer Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing the progression risk from Barrett's metaplasia to esophageal adenocarcinoma are challenging due to subjective microscopic classification and the need for objective risk determination, as they lack reliable markers for early intervention and discrimination between stable and progressive disease states.
Innovation Solution
A method involving DNA sequencing amplification, detection of mutations in microsatellite regions, categorization of clonality, and calculation of mutational load to predict disease progression risk, using specific microsatellite regions and weighting for low and high clonality mutations, and DNA microsatellite instability, allowing for risk categorization and treatment modalities selection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If subjective microscopic classification is used for diagnosing disease progression risk, then diagnostic flexibility is maintained, but measurement precision and reliability are insufficient
Solution Approach 1:
The patent replaces subjective microscopic classification (mechanical/visual inspection) with molecular biology-based detection methods including DNA sequencing, mutation analysis, and gene expression profiling. This substitution transforms the diagnostic approach from subjective visual assessment to objective molecular measurement, significantly improving precision while the standardized protocols maintain manageable complexity
Solution Approach 2:
The patent introduces molecular biomarkers (mutations, gene expressions, protein markers) as intermediaries between the disease state and diagnostic assessment. These biomarkers serve as measurable proxies that objectively reflect disease progression risk, replacing direct microscopic evaluation of tissue morphology while providing quantifiable risk stratification
2Reliability
If no objective risk markers are used, then diagnostic simplicity is maintained, but reliability for early intervention is insufficient
Solution Approach 1:
The patent segments the diagnostic evaluation into multiple independent molecular assays targeting different aspects of carcinogenesis (e.g., specific mutations, gene expressions, protein markers). Each assay targets a specific molecular feature with high sensitivity, and the combination of multiple segmented assessments provides comprehensive and reliable risk prediction that overcomes the limitations of any single marker
Solution Approach 2:
The patent employs preliminary molecular testing to identify high-risk patients before clinical progression occurs. By detecting molecular alterations early in the carcinogenic process (such as dysplastic changes at the molecular level), the system enables early intervention while the standardized detection protocols ensure reliable and reproducible results across different clinical settings
3Measurement precision
If histology-based diagnosis is used, then established diagnostic criteria are maintained, but objectivity and independence from histological variation are lost
Solution Approach 1:
The patent replaces histology-based diagnosis (microscopic tissue examination) with molecular biology methods including DNA extraction, sequencing, and gene expression analysis. This substitution eliminates inter-observer variability inherent in histological assessment and provides objective, quantifiable molecular profiles that independently predict disease progression risk without relying on histological interpretation
Solution Approach 2:
The patent develops molecular biomarkers that are universally applicable across different histological presentations and patient populations. The molecular assays can detect carcinogenic risk regardless of specific histological patterns, providing a universal diagnostic tool that transcends histological variation and enables consistent risk stratification across diverse clinical scenarios
Data Source
AI summary
Disclosed herein are methods for treating Barrett's metaplasia and esophageal adenocarcinoma and methods for determining mutational load as a predictor of the risk of disease progression from Barrett's metaplasia to esophageal adenocarcinoma.